TIM-3 inhibitors: a promising strategy for tumor immunotherapy

Trends Mol Med. 2024 Jan 31:S1471-4914(24)00004-2. doi: 10.1016/j.molmed.2024.01.004. Online ahead of print.ABSTRACTMa et al. recently reported a systematic screening of small-molecule compounds targeting the FG-CC' cleft of T cell immunoglobulin and mucin-containing molecule 3 (TIM-3). They identified a functional Tim-3 inhibitor, ML-T7, that, as a single agent or in combination with anti-PD-1, demonstrated strong antitumor activity in preclinical mouse tumor models, supporting its potential for further clinical translation.PMID:38302316 | DOI:10.1016/j.molmed.2024.01.004
Source: Trends in Molecular Medicine - Category: Molecular Biology Authors: Source Type: research